Skip to main content
Log in

Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro)

A Viewpoint by Marek Jutel

  • Adis Drug Profiles
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Bousquet J, VanCauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. ARIA Workshop Group. J Allergy Clin Immunol 2001 Nov; 108 (5 Suppl.): S147–334

    Article  PubMed  CAS  Google Scholar 

  2. Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Eng J Med 1999 Aug 12; 341(7): 468–75

    Article  CAS  Google Scholar 

  3. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002 Apr; 57(4): 306–12

    Article  PubMed  CAS  Google Scholar 

  4. Wheeler AW, Marshall JS, Ulrich JT. A Thl-inducing adjuvant, MPL®, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001 Oct; 126(2): 135–9

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jutel, M. Ultra-Short-Course Seasonal Allergy Vaccine (Pollinex® Quattro). Drugs 66, 939 (2006). https://doi.org/10.2165/00003495-200666070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200666070-00005

Keywords

Navigation